BIOTECH Patent News

View more issues:

Articles in March, 2006 issue of BIOTECH Patent News

• Mannatech enforces its ambrotose patent against nutritional supplements firm.
• Solulink introduces a biotinylation reagent with built-in biotin quantification.
• ThermoGenesis receives allowance of third patent for autologous thrombin processing device.
• EntreMed presents preclinical results for combination therapy with 2ME2 in brain and colon cancer.
• University of Texas obtains United States patent.(in partnership with University of Florida)(Brief article)
• Pennsylvania State University obtains United States patent.
• Licentia obtains United States patent.
• Chromos signs agreement with AppTec to manufacture multiple sclerosis drug.
• AIDS group lauds WHO report urging ease of drug patents in poor countries.
• Summit's licensing agreement with BioGenesis key to Nigerian environmental cleanup project.
• Anderson obtains United States patent.(Brief article)
• GlaxoSmithKline and Sirna form major alliance in RNAi-based therapeutics for respiratory disease.
• Wyeth forms translational collaboration with universities in Scotland.
• Large Scale Biology obtains United States patent.
• Zygogen licenses transgenic zebrafish technology to DanioLabs for internal drug discovery.
• Idenix licenses valopicitabine to Novartis.
• Schering obtains United States patent.
• Oragenics seeks patent for agent to treat obesity.
• Argentis to market dry eye treatment patented by Southern College of Optometry.
• Wyeth acquires an additional stake in Wyeth K.K. Japan.
• CEL-SCI files patent application for prevention/treatment of avian flu.
• Incorporated Administrative Agency obtains United States patent.
• HemoCue will enforce decision in patent infringement suit against EKF.
• Pharmacopeia licenses hypertension, congestive heart failure and diabetic nephropathy candidates from Bristol-Myers Squibb.
• Diversa obtains United States patent.
• Ludwig Institute obtains United States patent.
• Senesco obtains United States patent.
• Innovex and StoneBrige Pharma form parternship.
• Biosite and Oxford Genome Sciences form colorectal cancer collaboration.
• Sirna granted first broad siRNA patent for a gene target.(Sirna Therapeutics Inc.)
• Nabi acquires exclusive rights to Phase III organ transplantation rejection antibody product.
• Max-Planck obtains United States patent.(Max-Planck-Gesellschaft zur Forderung der Wissenchaften e.V.)(Brief article)
• Salk Institute obtains United States patent.